Reni J. Benjamin
Stock Analyst at JMP Securities
(2.84)
# 1,863
Out of 5,005 analysts
8
Total ratings
66.67%
Success rate
27.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $21.43 | +86.65% | 2 | Sep 3, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $35.65 | - | 1 | Aug 22, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $4 → $3 | $2.05 | +46.34% | 1 | Aug 21, 2025 | |
| PRLD Prelude Therapeutics | Maintains: Market Outperform | $4 → $3 | $1.47 | +104.08% | 1 | Aug 18, 2025 | |
| BCAB BioAtla | Downgrades: Market Perform | n/a | $0.69 | - | 1 | Aug 13, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $22 → $10 | $8.37 | +19.47% | 1 | Aug 12, 2025 | |
| KURA Kura Oncology | Maintains: Market Outperform | $28 → $24 | $9.57 | +150.78% | 1 | Aug 11, 2025 |
Summit Therapeutics
Sep 3, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $21.43
Upside: +86.65%
Inhibrx Biosciences
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $35.65
Upside: -
Werewolf Therapeutics
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $2.05
Upside: +46.34%
Prelude Therapeutics
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $1.47
Upside: +104.08%
BioAtla
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.69
Upside: -
Bicycle Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $8.37
Upside: +19.47%
Kura Oncology
Aug 11, 2025
Maintains: Market Outperform
Price Target: $28 → $24
Current: $9.57
Upside: +150.78%